U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C32H41NO2
Molecular Weight 471.6746
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TERFENADINE

SMILES

CC(C)(C)c1ccc(cc1)C(CCCN2CCC(CC2)C(c3ccccc3)(c4ccccc4)O)O

InChI

InChIKey=GUGOEEXESWIERI-UHFFFAOYSA-N
InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C32H41NO2
Molecular Weight 471.6746
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Terfenadine under brand name Seldane was used for the treatment of allergic rhinitis and allergic skin disorders but was withdrawn because of the serious side effect, heart rhythm problems. Terfenadine is a potent antagonist of histamine H1-receptor-mediated responses.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
40.0 nM [Ki]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.544 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.519 ng/mL
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
458.1 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
406.9 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.864 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
44.341 ng × h/mL
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2712.1 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
2720.1 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.6 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
12.6 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
180 mg 2 times / day multiple, oral
Highest studied dose
Dose: 180 mg, 2 times / day
Route: oral
Route: multiple
Dose: 180 mg, 2 times / day
Sources: Page: p.203
healthy, 18-40
n = 24
Health Status: healthy
Age Group: 18-40
Sex: M
Population Size: 24
Sources: Page: p.203
Other AEs: Electrocardiogram QTc interval prolonged...
Other AEs:
Electrocardiogram QTc interval prolonged (12.5%)
Sources: Page: p.203
60 mg 2 times / day multiple, oral
Recommended
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.69
unhealthy, 18-45
n = 24
Health Status: unhealthy
Condition: Seasonal allergic rhinitis
Age Group: 18-45
Sex: M
Population Size: 24
Sources: Page: p.69
Disc. AE: Headache...
Other AEs: Somnolence...
AEs leading to
discontinuation/dose reduction:
Headache (grade 2-3, 8.3%)
Other AEs:
Somnolence (grade 1, 4.15%)
Sources: Page: p.69
120 mg 1 times / day multiple, oral
Recommended
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources: Page: p.462
unhealthy, 19-66
n = 41
Health Status: unhealthy
Condition: Adverse reactions to specific immunotherapy with Hymenoptera venom
Age Group: 19-66
Sex: M+F
Population Size: 41
Sources: Page: p.462
Disc. AE: Nausea, Headache...
AEs leading to
discontinuation/dose reduction:
Nausea (2.4%)
Headache (2.4%)
Sources: Page: p.462
60 mg single, oral
Recommended
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources: Page: p.406
healthy, 23-40
n = 12
Health Status: healthy
Age Group: 23-40
Sex: M
Population Size: 12
Sources: Page: p.406
240 mg single, oral
Highest studied dose
Dose: 240 mg
Route: oral
Route: single
Dose: 240 mg
Sources: Page: p.610
healthy, 23-47
n = 12
Health Status: healthy
Age Group: 23-47
Sex: F
Population Size: 12
Sources: Page: p.610
Other AEs: Driving ability disturbed...
Other AEs:
Driving ability disturbed
Sources: Page: p.610
AEs

AEs

AESignificanceDosePopulation
Electrocardiogram QTc interval prolonged 12.5%
180 mg 2 times / day multiple, oral
Highest studied dose
Dose: 180 mg, 2 times / day
Route: oral
Route: multiple
Dose: 180 mg, 2 times / day
Sources: Page: p.203
healthy, 18-40
n = 24
Health Status: healthy
Age Group: 18-40
Sex: M
Population Size: 24
Sources: Page: p.203
Somnolence grade 1, 4.15%
60 mg 2 times / day multiple, oral
Recommended
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.69
unhealthy, 18-45
n = 24
Health Status: unhealthy
Condition: Seasonal allergic rhinitis
Age Group: 18-45
Sex: M
Population Size: 24
Sources: Page: p.69
Headache grade 2-3, 8.3%
Disc. AE
60 mg 2 times / day multiple, oral
Recommended
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.69
unhealthy, 18-45
n = 24
Health Status: unhealthy
Condition: Seasonal allergic rhinitis
Age Group: 18-45
Sex: M
Population Size: 24
Sources: Page: p.69
Headache 2.4%
Disc. AE
120 mg 1 times / day multiple, oral
Recommended
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources: Page: p.462
unhealthy, 19-66
n = 41
Health Status: unhealthy
Condition: Adverse reactions to specific immunotherapy with Hymenoptera venom
Age Group: 19-66
Sex: M+F
Population Size: 41
Sources: Page: p.462
Nausea 2.4%
Disc. AE
120 mg 1 times / day multiple, oral
Recommended
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources: Page: p.462
unhealthy, 19-66
n = 41
Health Status: unhealthy
Condition: Adverse reactions to specific immunotherapy with Hymenoptera venom
Age Group: 19-66
Sex: M+F
Population Size: 41
Sources: Page: p.462
Driving ability disturbed
240 mg single, oral
Highest studied dose
Dose: 240 mg
Route: oral
Route: single
Dose: 240 mg
Sources: Page: p.610
healthy, 23-47
n = 12
Health Status: healthy
Age Group: 23-47
Sex: F
Population Size: 12
Sources: Page: p.610
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
likely (co-administration study)
Comment: From abstract: a drug interaction between terfenadine and ketoconazole resulted in the elevated terfenadine levels in plasma and in the cardiotoxicity previously seen only in cases of terfenadine overdose.
Page: 1.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Mechanism of terfenadine block of ATP-sensitive K(+) channels.
2000 Aug
A structural basis for drug-induced long QT syndrome.
2000 Oct 24
Effect of oxatomide, an antiallergic agent, on QT interval in dogs.
2001
Saquinavir soft gelatin capsule: a comparative safety review.
2001
Problems of heart rate correction in assessment of drug-induced QT interval prolongation.
2001 Apr
Newer antihistamines.
2001 Apr 30
Identification of functionally variant MDR1 alleles among European Americans and African Americans.
2001 Aug
Ugly wait at the counter. Insurer pushes to make allergy drugs nonprescription.
2001 Aug 6
Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.
2001 Feb
Comparison of montelukast and fexofenadine for chronic idiopathic urticaria.
2001 Jan
Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
2001 Mar
Fexofenadine hydrochloride--a new anti-histaminic drug.
2001 Mar
Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
2001 May
Roles of mast cells and histamine in mosquito bite-induced allergic itch-associated responses in mice.
2001 May
A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis.
2001 May
Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis.
2001 May
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
2001 May
Fexofenadine reduces nasal congestion in perennial allergic rhinitis.
2001 Nov
Assay of terfenadine in pharmaceutical formulation and human plasma by adsorptive stripping voltammetry.
2001 Nov
Development and evaluation of high throughput functional assay methods for HERG potassium channel.
2001 Oct
An amino acid residue whose change by mutation affects drug binding to the HERG channel.
2001 Oct 12
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
2001 Oct 26
Potential cardiac toxicity of H1-antihistamines.
2002
[Comparative antihistamine and anti-allergic effects of various antihistamine preparations].
2002
Pharmacokinetic profile of zafirlukast.
2002
[Hay fever and asthma. Many of your patients have both].
2002 Apr 25
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
2002 Aug
Cardiotoxicity of new antihistamines and cisapride.
2002 Feb 28
An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers.
2002 Jan
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis.
2002 Jan
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
2002 Jan
Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry.
2002 Jan 25
Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness.
2002 Jul
Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes.
2002 Jul
Chronic urticaria and angioedema.
2002 Jul 18
Simultaneous determination of fexofenadine and its related compounds by HPLC.
2002 Jul 20
Drug eruption and liver injury caused by terfenadine and oxatomide.
2002 Jul-Aug
Effect of St John's wort on the pharmacokinetics of fexofenadine.
2002 Jun
Are herbal products dietary supplements or drugs? An important question for public safety.
2002 Jun
Next generation antihistamines: therapeutic rationale, accomplishments and advances.
2002 Jun
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
2002 Jun 18
Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines.
2002 May
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
2002 May
Delineation of the protective action of zinc sulfate on ulcerative colitis in rats.
2002 May 17
Do standard doses of frequently prescribed drugs cause preventable adverse effects in women?
2002 Spring
Patents

Sample Use Guides

Terfenadine 20 mg 3 times a day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:10:44 UTC 2021
Edited
by admin
on Fri Jun 25 21:10:44 UTC 2021
Record UNII
7BA5G9Y06Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TERFENADINE
EP   HSDB   INN   JAN   MART.   MI   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
TERFENADINE [EP]
Common Name English
TERFENADINE [WHO-DD]
Common Name English
TERFENADINE [MART.]
Common Name English
NSC-758627
Code English
SELDANE
Brand Name English
TERFENADINE [EP MONOGRAPH]
Common Name English
TERFENADINE [MI]
Common Name English
TERFENADINE [JAN]
Common Name English
TERFENADINE [HSDB]
Common Name English
.ALPHA.-(P-TERT-BUTYLPHENYL)-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL
Common Name English
TERFENADINE [USAN]
Common Name English
RMI 9918
Code English
NSC-665802
Code English
TERFENADINE [INN]
Common Name English
TERFENADINE [VANDF]
Common Name English
1-PIPERIDINEBUTANOL, .ALPHA.-(4-(1,1-DIMETHYLETHYL)PHENYL)-4-(HYDROXYDIPHENYLMETHYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
WHO-ATC R06AX12
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
WHO-VATC QR06AX12
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
LIVERTOX 939
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
Code System Code Type Description
MESH
D016593
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
ECHA (EC/EINECS)
256-710-8
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
WIKIPEDIA
Terfenadine
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
CAS
50679-08-8
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
EVMPD
SUB10920MIG
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
NCI_THESAURUS
C29494
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
INN
3674
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
FDA UNII
7BA5G9Y06Q
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
RXCUI
42330
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
2600
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
ChEMBL
CHEMBL17157
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
MERCK INDEX
M10576
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY Merck Index
IUPHAR
2608
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
PUBCHEM
5405
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
EPA CompTox
50679-08-8
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
DRUG BANK
DB00342
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
HSDB
6508
Created by admin on Fri Jun 25 21:10:45 UTC 2021 , Edited by admin on Fri Jun 25 21:10:45 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY